154 related articles for article (PubMed ID: 37854018)
1. Proteomics on malignant pleural effusions reveals ERα loss in metastatic breast cancer associates with SGK1-NDRG1 deregulation.
Mayayo-Peralta I; Debets DO; Prekovic S; Schuurman K; Beerthuijzen S; Almekinders M; Sanders J; Moelans CB; Saleiro S; Wesseling J; van Diest PJ; Henrique R; Jerónimo C; Altelaar M; Zwart W
Mol Oncol; 2024 Jan; 18(1):156-169. PubMed ID: 37854018
[TBL] [Abstract][Full Text] [Related]
2. Serum and glucocorticoid-regulated kinase 1 (SGK1) activation in breast cancer: requirement for mTORC1 activity associates with ER-alpha expression.
Hall BA; Kim TY; Skor MN; Conzen SD
Breast Cancer Res Treat; 2012 Sep; 135(2):469-79. PubMed ID: 22842983
[TBL] [Abstract][Full Text] [Related]
3. Loss of steroid hormone receptors is common in malignant pleural and peritoneal effusions of breast cancer patients treated with endocrine therapy.
Schrijver WAME; Schuurman K; van Rossum A; ; Peeters T; Ter Hoeve N; Zwart W; van Diest PJ; Moelans CB
Oncotarget; 2017 Aug; 8(33):55550-55561. PubMed ID: 28903441
[TBL] [Abstract][Full Text] [Related]
4. Regulation of breast cancer metastasis by Runx2 and estrogen signaling: the role of SNAI2.
Chimge NO; Baniwal SK; Little GH; Chen YB; Kahn M; Tripathy D; Borok Z; Frenkel B
Breast Cancer Res; 2011; 13(6):R127. PubMed ID: 22151997
[TBL] [Abstract][Full Text] [Related]
5. The pioneer factor PBX1 is a novel driver of metastatic progression in ERα-positive breast cancer.
Magnani L; Patten DK; Nguyen VT; Hong SP; Steel JH; Patel N; Lombardo Y; Faronato M; Gomes AR; Woodley L; Page K; Guttery D; Primrose L; Fernandez Garcia D; Shaw J; Viola P; Green A; Nolan C; Ellis IO; Rakha EA; Shousha S; Lam EW; Győrffy B; Lupien M; Coombes RC
Oncotarget; 2015 Sep; 6(26):21878-91. PubMed ID: 26215677
[TBL] [Abstract][Full Text] [Related]
6. The proteasome inhibitor Bortezomib (Velcade) as potential inhibitor of estrogen receptor-positive breast cancer.
Thaler S; Thiede G; Hengstler JG; Schad A; Schmidt M; Sleeman JP
Int J Cancer; 2015 Aug; 137(3):686-97. PubMed ID: 25530422
[TBL] [Abstract][Full Text] [Related]
7. MAF amplification licenses ERα through epigenetic remodelling to drive breast cancer metastasis.
Llorente A; Blasco MT; Espuny I; Guiu M; Ballaré C; Blanco E; Caballé A; Bellmunt A; Salvador F; Morales A; Nuñez M; Loren G; Imbastari F; Fidalgo M; Figueras-Puig C; Gibler P; Graupera M; Monteiro F; Riera A; Holen I; Avgustinova A; Di Croce L; Gomis RR
Nat Cell Biol; 2023 Dec; 25(12):1833-1847. PubMed ID: 37945904
[TBL] [Abstract][Full Text] [Related]
8. Notch3 Maintains Luminal Phenotype and Suppresses Tumorigenesis and Metastasis of Breast Cancer via Trans-Activating Estrogen Receptor-α.
Dou XW; Liang YK; Lin HY; Wei XL; Zhang YQ; Bai JW; Chen CF; Chen M; Du CW; Li YC; Tian J; Man K; Zhang GJ
Theranostics; 2017; 7(16):4041-4056. PubMed ID: 29109797
[TBL] [Abstract][Full Text] [Related]
9. An oestrogen-dependent model of breast cancer created by transformation of normal human mammary epithelial cells.
Duss S; André S; Nicoulaz AL; Fiche M; Bonnefoi H; Brisken C; Iggo RD
Breast Cancer Res; 2007; 9(3):R38. PubMed ID: 17573968
[TBL] [Abstract][Full Text] [Related]
10. Cryptotanshinone inhibition of mammalian target of rapamycin pathway is dependent on oestrogen receptor alpha in breast cancer.
Pan Y; Shi J; Ni W; Liu Y; Wang S; Wang X; Wei Z; Wang A; Chen W; Lu Y
J Cell Mol Med; 2017 Sep; 21(9):2129-2139. PubMed ID: 28272775
[TBL] [Abstract][Full Text] [Related]
11. Dependence receptor UNC5A restricts luminal to basal breast cancer plasticity and metastasis.
Padua MB; Bhat-Nakshatri P; Anjanappa M; Prasad MS; Hao Y; Rao X; Liu S; Wan J; Liu Y; McElyea K; Jacobsen M; Sandusky G; Althouse S; Perkins S; Nakshatri H
Breast Cancer Res; 2018 May; 20(1):35. PubMed ID: 29720215
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-135b regulates ERα, AR and HIF1AN and affects breast and prostate cancer cell growth.
Aakula A; Leivonen SK; Hintsanen P; Aittokallio T; Ceder Y; Børresen-Dale AL; Perälä M; Östling P; Kallioniemi O
Mol Oncol; 2015 Aug; 9(7):1287-300. PubMed ID: 25907805
[TBL] [Abstract][Full Text] [Related]
13. Expression of estrogen receptor beta and phosphorylation of estrogen receptor alpha serine 167 correlate with progression-free survival in patients with metastatic breast cancer treated with aromatase inhibitors.
Motomura K; Ishitobi M; Komoike Y; Koyama H; Nagase H; Inaji H; Noguchi S
Oncology; 2010; 79(1-2):55-61. PubMed ID: 21071990
[TBL] [Abstract][Full Text] [Related]
14. Expression of insulin receptor substrate 1 in primary breast cancer and lymph node metastases.
Koda M; Sulkowska M; Kanczuga-Koda L; Sulkowski S
J Clin Pathol; 2005 Jun; 58(6):645-9. PubMed ID: 15917419
[TBL] [Abstract][Full Text] [Related]
15. Altered expression and activation of the nerve growth factor receptors TrkA and p75 provide the first evidence of tumor progression to effusion in breast carcinoma.
Davidson B; Reich R; Lazarovici P; Ann Flørenes V; Nielsen S; Nesland JM
Breast Cancer Res Treat; 2004 Jan; 83(2):119-28. PubMed ID: 14997042
[TBL] [Abstract][Full Text] [Related]
16. Clinically relevant CHK1 inhibitors abrogate wild-type and Y537S mutant ERα expression and proliferation in luminal primary and metastatic breast cancer cells.
Pescatori S; Leone S; Cipolletti M; Bartoloni S; di Masi A; Acconcia F
J Exp Clin Cancer Res; 2022 Apr; 41(1):141. PubMed ID: 35418303
[TBL] [Abstract][Full Text] [Related]
17. Estrogen receptor alpha prevents bladder cancer via INPP4B inhibited akt pathway in vitro and in vivo.
Hsu I; Yeh CR; Slavin S; Miyamoto H; Netto GJ; Tsai YC; Muyan M; Wu XR; Messing EM; Guancial EA; Yeh S
Oncotarget; 2014 Sep; 5(17):7917-35. PubMed ID: 25277204
[TBL] [Abstract][Full Text] [Related]
18. Phosphorylation of ERalpha at serine 118 in primary breast cancer and in tamoxifen-resistant tumours is indicative of a complex role for ERalpha phosphorylation in breast cancer progression.
Sarwar N; Kim JS; Jiang J; Peston D; Sinnett HD; Madden P; Gee JM; Nicholson RI; Lykkesfeldt AE; Shousha S; Coombes RC; Ali S
Endocr Relat Cancer; 2006 Sep; 13(3):851-61. PubMed ID: 16954434
[TBL] [Abstract][Full Text] [Related]
19. Loss of ERα induces amoeboid-like migration of breast cancer cells by downregulating vinculin.
Gao Y; Wang Z; Hao Q; Li W; Xu Y; Zhang J; Zhang W; Wang S; Liu S; Li M; Xue X; Zhang W; Zhang C; Zhang Y
Nat Commun; 2017 Mar; 8():14483. PubMed ID: 28266545
[TBL] [Abstract][Full Text] [Related]
20. Cell lineage tracing links ERα loss in Erbb2-positive breast cancers to the arising of a highly aggressive breast cancer subtype.
Ding Y; Liu Y; Lee DK; Tong Z; Yu X; Li Y; Xu Y; Lanz RB; O'Malley BW; Xu J
Proc Natl Acad Sci U S A; 2021 May; 118(21):. PubMed ID: 34006643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
